Biotech News

Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026

Pacira BioSciences (PCRX)Pacira BioSciences2026-04-16 12:00 ESTEarnings

BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter 2026 financial results after

Pacira BioSciences

Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program. EXPAREL EXPAREL is a multivesicular-liposome formulation of bupivacaine...

Recent company news

PCRXPacira BioSciences2026-08-07 12:00 EST

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PCRXPacira BioSciences2026-08-06 12:00 EST

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

PCRXPacira BioSciences2026-08-04 20:01 EST

Pacira BioSciences Reports Second Quarter 2026 Financial Results

PCRXPacira BioSciences2026-07-28 12:00 EST

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

PCRXPacira BioSciences2026-07-27 12:00 EST

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Stock data

Close: 25.58 USD
Market cap: 875.49M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States